ClinicalTrials.gg

Program

corabotase

Also written as “Corabotase”, “Corabotase dose A” and “Corabotase dose B”.

Its studies are mostly in Migraine Disorders · Torticollis, led by Ipsen.

Furthest: phase 3, since Feb 17, 20266 company-led studies, 6 open or runningNext primary completion: Dec 15, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ipsen66 open or runningphase 3since Feb 17, 2026Mar 26, 2021Dec 15, 2026phase 3 · NCT07435428

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2021First study: phase 2 study in Moderate to Severe Upper Facial LinesFirst studyNCT04821089 · 727 enrolled · France, Germany
  2. Oct 1, 2024Phase 2 study in Episodic MigraineNCT06625060 · 670 enrolled · United States, Australia, Brazil and more
  3. Apr 14, 2025Phase 2 study in TorticollisNCT06937931 · 132 planned · United States, Czechia, France and more
  4. Feb 17, 20262 phase 3 studies in Moderate to Severe Glabellar LinesPhase 3 reachedNCT07435428, NCT07427797
  5. Aug 19, 2026Phase 3 study in Moderate to Severe Glabellar LinesNCT07779252 · 160 planned · China
  6. Oct 6, 2026Primary completion moved from 2026-08-31 to 2027-08-19Date moved laterphase 2 · +12 months · NCT04821089

Ahead

  1. Dec 15, 2026Primary completion: phase 3 study in Moderate to Severe Glabellar LinesNCT07435428
  2. Dec 15, 2026Primary completion: phase 3 study in Moderate to Severe Glabellar LinesNCT07427797
  3. Mar 26, 2027Primary completion: phase 2 study in TorticollisNCT06937931
  4. Aug 19, 2027Primary completion: phase 2 study in Moderate to Severe Upper Facial LinesNCT04821089

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07779252Moderate to Severe Glabellar Lines · China3RecruitingApr 10, 2028160
NCT07435428Moderate to Severe Glabellar Lines · United States, France, Germany and more3Active, not recruitingDec 15, 20261,300
NCT07427797Moderate to Severe Glabellar Lines · United States, Canada3Active, not recruitingDec 15, 2026309
NCT06937931Torticollis · United States, Czechia, France and more2RecruitingMar 26, 2027132
NCT06625060Episodic Migraine · United States, Australia, Brazil and more2Active, not recruitingOct 31, 2027670
NCT04821089Moderate to Severe Upper Facial Lines · France, Germany2Active, not recruitingAug 19, 2027727

How it is read

Names in the registry

  • “Corabotase”, 6 entries
  • “Corabotase dose A”, 1 entry
  • “Corabotase dose B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.